A Review of the Use of Direct Oral Anticoagulants for Treating Venous Thromboembolism in Patients with Cancer

Authors

  • Grant T Fankhauser Assistant Professor of Surgery University of Texas Medical Branch Galveston Texas USA

DOI:

https://doi.org/10.37591/rrjooh.v7i2.348

Abstract

Venous thromboembolism is a common complication in patients with cancer. Treatment guidelines have long recommended low molecular weight heparin as the first-line therapy. There is a growing body of literature regarding direct oral anticoagulants in treating venous thromboembolism in these patients. The data regarding the use of direct oral anticoagulants in this population is reviewed as are the most current guidelines from the National Comprehensive Cancer Network.

 

Keywords: Anticoagulants, venous thromboembolism, heparin, cancer network

Cite this Article

Fankhauser Grant T. A Review of the Use of Direct Oral Anticoagulants for Treating Venous Thromboembolism in Patients with Cancer. Research & Reviews: Journal of Oncology & Hematology. 2018; 7(2): 15–17p.

Downloads

Published

2018-09-14

Issue

Vol. 7 No. 2 (2018)

Section

Review Article

License

Declaration and Copyright Transfer Form

(to be completed by authors)

I/ We, the undersigned author(s) of the submitted manuscript, hereby declare, that the above manuscript which is submitted for publication in the STM Journals(s), is not published already in part or whole (except in the form of abstract) in any journal or magazine for private or public circulation, and, is not under consideration of publication elsewhere.

  • I/We will not withdraw the manuscript after 1 week of submission as I have read the Author Guidelines and will adhere to the guidelines.
  • I/We Author(s ) have niether given nor will give this manuscript elsewhere for publishing after submitting in STM Journal(s).
  • I/ We have read the original version of the manuscript and am/ are responsible for the thought contents embodied in it. The work dealt in the manuscript is my/ our own, and my/ our individual contribution to this work is significant enough to qualify for authorship.
  •  I/We also agree to the authorship of the article in the following order:

Author’s name                                    

 

1. ________________

2. ________________

3. ________________

4. ________________

 

We  Author(s) tick this box and would request you to consider it as our signature as we agree to the terms of this Copyright Notice, which will apply to this submission if and when it is published by this journal.